Continued shortage of Haemophilus influenzae type b (Hib) conjugate vaccines and potential implications for hib surveillance - United States, 2008

Morbidity and Mortality Weekly Report

Volumn 57, Issue 46, 2008, Pages 1252-1255

  Coronado, F ^a   Brown, K ^a   Cohn, A ^a   Messonnier, N ^a   Clark, T A ^a   Jackson, M ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CDC ^*

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE-TYPE B POLYSACCHARIDE-NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN CONJUGATE VACCINE; HAEMOPHILUS VACCINE; HEPATITIS B VACCINE; OUTER MEMBRANE PROTEIN;

CLASSIFICATION; DRUG CONTROL; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HUMAN; IMMUNIZATION; INFANT; NOTE; PRESCHOOL CHILD; SEROTYPING; UNITED STATES;

BACTERIAL OUTER MEMBRANE PROTEINS; CHILD, PRESCHOOL; DRUG AND NARCOTIC CONTROL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; POLYSACCHARIDES, BACTERIAL; POPULATION SURVEILLANCE; SEROTYPING; UNITED STATES;

EID: 57349161894     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. CDC. Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB® and Comvax®). MMWR 2007;56:1318-20.
2. Ward J, Lieberman JM, Cochi SL. Haemophilus influenzae vaccines. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed. Philadelphia, PA: WB Saunders Co.; 1994:337-86.
3. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a child vaccine preventable disease. Emerg Infect Dis 1998;4:229-37.
4. Schuchat A, Hilger T, Zell E, et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 2001;7:92-9.
5. Kayhty H, Eskola J, Peltola H, Stout MG, Samuelson JS, Gordon LK. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J Infect Dis 1987;155:100-6.
6. CDC. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: recommendations of the ACIP. MMWR 1991;40 (No. RR-1).
7. Fernandez J, Levine OS, Sanchez J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 2000;182:1553-6.
8. CDC. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children - United States, 1998-2000. MMWR 2002;51:234-7.
9. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003;188:481-5.
10. LaClaire LL, Tondella ML, Beall DS, et al. Identification of Haemophilus influenzae serotypes by standard slide agglutination serotyping and PCR-based capsule typing. J Clin Microbiol 2003;41:393-6.